Traws Pharma, Inc. (TRAW)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | 8-K (2026-05-15) · 99.1 | ||
| 10-K/A | FY-2024 | |||
| 10-KLatest | FY-2024 | 8-K (2026-04-15) · 99.1 | 8-K (2025-03-31) · 99.1 · 99.2 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-13) · 99.1 · 99.2 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-14) · 99.1 · 99.2 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-15) · 99.1 | ||
| 10-K/A | FY-2024 | |||
| 10-K | FY-2024 | 8-K (2026-04-15) · 99.1 | 8-K (2025-03-31) · 99.1 · 99.2 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-14) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-15) · 99.1 | 8-K (2024-05-16) · 99.1 | ||
| 10-Q | Q1-2024 | — | ||
| 10-K/A | FY-2023 | |||
| 10-K | FY-2023 | — | ||
| 10-Q | Q3-2023 | 8-K (2023-11-14) · 99.1 | ||
| 10-Q | Q2-2023 | 8-K (2023-08-10) · 99.1 | ||
| 10-K/A | FY-2022 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Commitments and Contingencies (details) | — |
|
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations | ||
| Condensed Consolidated Statements of Comprehensive (loss) Income | — |
|
| Consolidated Statements of Comprehensive Income (loss) | ||
| Consolidated Statements of Comprehensive Loss | ||
| Consolidated Statement of Convertible Preferred Stock and Stockholders' (deficit) Equity (unaudited) | — |
|
| Consolidated Statement of Convertible Preferred Stock and Stockholders' Deficit | — |
|
| Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (deficit) (unaudited) | — |
|
| Consolidated Statement of Redeemable Convertible Preferred Stock and Stockholders' (deficit) Equity (unaudited) | — |
|
| Consolidated Statement of Stockholders' Equity (deficit) (unaudited) | — |
|
| Consolidated Statements of Stockholders' Equity | — |
|
| Consolidated Statements of Cash Flows | ||
| Notes | ||
| Asset Acquisition | ||
| Balance Sheet Detail | ||
| Commitments and Contingencies | ||
| Convertible Preferred Stock and Stockholders' Equity (deficit) | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Employee Benefit Plan | — |
|
| Fair Value Measurements | — |
|
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Intangible Assets | ||
| License and Collaboration Agreements | — |
|
| Nature of Business | ||
| Net Loss Per Share of Common Stock | ||
| Pay Vs Performance Disclosure | ||
| Property and Equipment | — |
|
| Redeemable Convertible Preferred Stock Stockholders' (deficit) Equity | ||
| Research Agreements | ||
| Research and Development Arrangements and Related Party Transactions | ||
| Restructuring | ||
| Revenue | ||
| Securities Registrations and Sales Agreements | — |
|
| Segment Information | ||
| Stock-based Compensation | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | ||
| Warrants | ||